Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

Judson, Ian; Verweij, Jaap; Gelderblom, Hans; Hartmann, Jorg T.; Schoeffski, Patrick; Blay, Jean-Yves; Kerst, J. Martijn; Sufliarsky, Josef; Whelan, Jeremy; Hohenberger, Peter; Krarup-Hansen, Anders; Alcindor, Thierry; Marreaud, Sandrine; Litiere, Saskia; Hermans, Catherine; Fisher, Cyril; Hogendoorn, Pancras C. W.; dei Tos, A. Paolo; van der Graaf, Winette T. A.

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

Autor(en):

Judson, Ian; Verweij, Jaap; Gelderblom, Hans; Hartmann, Jorg T.; Schoeffski, Patrick; Blay, Jean-Yves; Kerst, J. Martijn; Sufliarsky, Josef; Whelan, Jeremy; Hohenberger, Peter; Krarup-Hansen, Anders; Alcindor, Thierry; Marreaud, Sandrine; Litiere, Saskia; Hermans, Catherine; Fisher, Cyril; Hogendoorn, Pancras C. W.; dei Tos, A. Paolo; van der Graaf, Winette T. A.

Tübinger Autor(en):

Hartmann, Jörg T.

Erschienen in:

Lancet Oncology (2014), Bd. 15, H. 4, S. 415-423

Verlagsangabe:

Elsevier Science Inc

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/S1470-2045(14)70063-4

ISSN:

1470-2045